By SPC Staff
The FDA approved natalizumab-sztn (Tyruko, Sandoz), the first biosimilar to treat multiple sclerosis (MS). The drug is a biosimilar to natalizumab (Tysabri, Biogen) injection for adults with relapsing forms of MS. Like natalizumab, the biosimilar is also indicated for adults with moderate to severe Crohn’s disease with evidence of inflammation.
For relapsing MS, natalizumab-sztn is approved to treat:
• clinically isolated syndrome, which is a single, first occurrence of MS